An Open-Label, First-In-Human, Dose Escalation Study Of A Novel Cd3-Cd123 Bispecific T-Cell Engager Administered As A Single Agent By Intravenous Infusion In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, Or High Risk Myelodysplastic Syndrome.